smyd3 links lysine methylation map3k2 ras-driven cancer 
deregulation lysine methylation signalling emerged common aetiological factor cancer pathogenesis inhibitors several histone lysine methyltransferases kmts developed chemotherapeutics largely cytoplasmic kmt smyd3 set mynd domain containing protein overexpressed numerous human tumours- however molecular mechanism smyd3 regulates cancer pathways relationship tumor-igenesisin vivo largely unknown show methylation map3k2 smyd3 increases map kinase signalling promotes formation ras-driven carcinomas using mouse models pancreatic ductal adenocarcinoma lung adenocarcinoma found abrogating smyd3 catalytic activity inhibits tumour development response oncogenic ras used protein array technology identify map3k2 kinase target smyd3 cancer cell lines smyd3-mediated methylation map3k2 lysine potentiates activation ras/raf/mek/erk signalling module smyd3 depletion synergizes mek inhibitor block ras-driven tumorigenesis finally pp2a phosphatase complex key negative regulator map kinase pathway binds map3k2 interaction blocked methylation together results elucidate new role lysine methylation integrating cytoplasmic kinase-signalling cascades establish pivotal role smyd3 regulation oncogenic ras signalling 
